Home ›
Lung Cancer Trials ›
NCT07332858
First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
This study aims to evaluate the safety of intrapleural injection of TolueneSulfonamide in patients with malignant pleural effusion and to explore its potential effectiveness.
Trial Details
NCT ID NCT07332858
Phase PHASE1 / PHASE2
Sponsor Gang Hou
Status RECRUITING
Cancer Type Lung Cancer
Interventions Intrapleural administration of TolueneSulfonamide Intrapleural administration of normal saline injection
Locations (sample) Beijing, Beijing Municipality, China|39.9075,116.39723
Key Eligibility Criteria
Age between 18 and 75 years (inclusive) at the time of signing the informed consent form. Histologically or cytologically confirmed malignant pleural effusion, with the primary tumor diagnosed as non-small cell lung cancer (NSCLC). Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of at least 3 months. Presence of dyspnea symptoms.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →